SECsense Logo

Halozyme Therapeutics, Inc. 8-K Report: Key Insights from February 18, 2025 Filing

$HALO
Form 8-K
Filed on: 2025-02-18
Source
Halozyme Therapeutics, Inc. 8-K Report: Key Insights from February 18, 2025 Filing

Based on the provided section of the financial report, here are the key pieces of information extracted:

  1. Entity Information:
  • Company Name: Halozyme Therapeutics, Inc.
  • CIK (Central Index Key): 0001159036
  • SEC File Number: 001-32335
  • Incorporation: Delaware (DE)
  • EIN (Employer Identification Number): 88-0488686
  • Address: 12390 El Camino Real, San Diego, CA 92130
  • Phone Number: 858-794-8889
  1. Filing Details:
  • Form Type: 8-K (Current Report)
  • Filing Date: February 18, 2025
  1. Stock Information:
  • Class of Stock: Common Stock
  • Par Value: $0.001
  • Stock Ticker: HALO
  • Exchange: NASDAQ
  1. Reporting Period:
  • Period Start Date: February 18, 2025
  • Period End Date: February 18, 2025

Insights:

  • The report is a current report (8-K), which typically indicates that it contains significant events or changes that are relevant to shareholders and the SEC.
  • Halozyme Therapeutics, Inc. is actively listed on NASDAQ under the ticker HALO, suggesting it is a publicly traded company, making it subject to SEC regulations and reporting requirements.
  • The filing date coincides with the reporting period, indicating that the information provided may pertain to a specific event occurring on that date.

This condensed information provides a snapshot of Halozyme Therapeutics, Inc. as of the specified filing date and can be critical for investors or stakeholders analyzing the company’s recent developments.